<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7122614/results/search/drug/results.xml">
  <result pre="also result in clinically significant adverse outcomes [10–13]. Keywords Influenza" exact="Amantadine" post="Rimantadine Laninamivir Oseltamivir Peramivir Zanamivir Neuraminidase M2 protein Favipiravir"/>
  <result pre="result in clinically significant adverse outcomes [10–13]. Keywords Influenza Amantadine" exact="Rimantadine" post="Laninamivir Oseltamivir Peramivir Zanamivir Neuraminidase M2 protein Favipiravir Antiviral"/>
  <result pre="significant adverse outcomes [10–13]. Keywords Influenza Amantadine Rimantadine Laninamivir Oseltamivir" exact="Peramivir" post="Zanamivir Neuraminidase M2 protein Favipiravir Antiviral resistance Introduction There"/>
  <result pre="adverse outcomes [10–13]. Keywords Influenza Amantadine Rimantadine Laninamivir Oseltamivir Peramivir" exact="Zanamivir" post="Neuraminidase M2 protein Favipiravir Antiviral resistance Introduction There are"/>
  <result pre="acids in the M2 gene result in cross-resistance to both" exact="amantadine" post="and rimantadine. Resistance emergence during therapy with neuraminidase inhibitors"/>
  <result pre="[17]. There are currently two approved M2 ion channel inhibitors," exact="amantadine" post="and rimantadine. Early studies demonstrated that influenza variants with"/>
  <result pre="Early studies demonstrated that influenza variants with high-level resistance to" exact="amantadine" post="and rimantadine could be selected in the laboratory though"/>
  <result pre="demonstrated that influenza variants with high-level resistance to amantadine and" exact="rimantadine" post="could be selected in the laboratory though in vitro"/>
  <result pre="of influenza A/H1N1, A/H2N2, and A/H3N2 were initially susceptible to" exact="amantadine" post="and rimantadine [19, 24, 39, 42]. Even after licensure"/>
  <result pre="A/H1N1, A/H2N2, and A/H3N2 were initially susceptible to amantadine and" exact="rimantadine" post="[19, 24, 39, 42]. Even after licensure of the"/>
  <result pre="the M2 inhibitors, possibly related to increased use of over-the-counter" exact="amantadine" post="after the emergence of severe acute respiratory syndrome (SARS)"/>
  <result pre="EIA enzyme immunoassay aAll resistant viruses from family members receiving" exact="rimantadine" post="bOver 80 % of tested isolates were H3N2 subtype"/>
  <result pre="resistant virus could be detected in 50 % of six" exact="rimantadine" post="recipients by day 3 of treatment, although the nasal"/>
  <result pre="33 % of 24 adult and pediatric household members receiving" exact="rimantadine" post="shed resistant virus on day 5 of treatment; none"/>
  <result pre="found emergence of resistant virus in 27 % of 37" exact="rimantadine" post="recipients, including 45 % of those still virus positive"/>
  <result pre="positive on day 7, compared to 6 % of 32" exact="acetaminophen" post="recipients [23]. Resistant virus was detected as early as"/>
  <result pre="on days 5–7. A study of Japanese children treated with" exact="amantadine" post="found that 30 % of 81 in the 1999–2000"/>
  <result pre="80 % of 15 hospitalized children during or immediately after" exact="amantadine" post="treatment [41]. Nine (75 %) of 12 children had"/>
  <result pre="randomized study patients hospitalized with influenza were to receive either" exact="rimantadine" post="alone or rimantadine plus nebulized zanamivir [54]. Rimantadine-resistant virus"/>
  <result pre="hospitalized with influenza were to receive either rimantadine alone or" exact="rimantadine" post="plus nebulized zanamivir [54]. Rimantadine-resistant virus was detected in"/>
  <result pre="were to receive either rimantadine alone or rimantadine plus nebulized" exact="zanamivir" post="[54]. Rimantadine-resistant virus was detected in 2/20 (10 %)"/>
  <result pre="[54]. Rimantadine-resistant virus was detected in 2/20 (10 %) of" exact="rimantadine" post="monotherapy patients, while non-resistant variants were detected in the"/>
  <result pre="No. (%) shedding resistant viruses Hall et al. [23] Children" exact="Rimantadine" post="37 10 (27 %) H3N2 Hayden et al. [25]"/>
  <result pre="10 (27 %) H3N2 Hayden et al. [25] 1987–1989 Children" exact="Rimantadine" post="21 6 (29 %) H3N2 Hayden et al. [27]"/>
  <result pre="6 (29 %) H3N2 Hayden et al. [27] 1988–1989 Adults" exact="Rimantadine" post="13 5 (38 %) H3N2 Englund et al. [28]"/>
  <result pre="(38 %) H3N2 Englund et al. [28] 1993–1994 Immunocompromised Amantadine," exact="rimantadine" post="15 5 (33 %) H3N2 Saito et al. [53]"/>
  <result pre="5 (33 %) H3N2 Saito et al. [53] 1999–2001 Children" exact="Amantadine" post="111 22 (33 %) H3N2 9 (20 %) H1N1"/>
  <result pre="(20 %) H1N1 Shirashi et al. [41] 1999–2001 Children (hospitalized)" exact="Amantadine" post="15 8 (100 %) H3N2 4 (57 %) H1N1"/>
  <result pre="Contact birds shedding resistant virus due to earlier incorporation of" exact="amantadine" post="in the drinking water of donors (4 days only)"/>
  <result pre="of four experiments over four cumulative transmission cycles. Households Both" exact="amantadine" post="and rimantadine are effective for postexposure prophylaxis of illness"/>
  <result pre="experiments over four cumulative transmission cycles. Households Both amantadine and" exact="rimantadine" post="are effective for postexposure prophylaxis of illness due to"/>
  <result pre="reduction in secondary influenza illness in household contacts receiving either" exact="amantadine" post="or rimantadine for postexposure prophylaxis, when the ill index"/>
  <result pre="secondary influenza illness in household contacts receiving either amantadine or" exact="rimantadine" post="for postexposure prophylaxis, when the ill index cases received"/>
  <result pre="(%) No./total evaluable (%) Active Control Galbraith et al. [208]" exact="Amantadine" post="(≥2 years) 1967–1968 (A/H2N2) No 0/91 (0 %) 12/90"/>
  <result pre="(0 %) 12/90 (13 %) 100 Bricaire et al. [209]" exact="Rimantadine" post="(≥1 year) 1988–1989 (A/not stated) No 8/151a (5 %)"/>
  <result pre="(5 %) 26/150a (17 %) 70 Monto et al. [210]" exact="Zanamivir" post="(≥5 years) 2000–2001 (A/H3N2, B) No 12/661 (2 %)"/>
  <result pre="(1 %) 34/462 (72 %) 89 Galbraith et al. [212]" exact="Amantadine" post="(≥2 years) 1968–1969 (A/H3N2) Yes 5/43 (12 %) 6/42"/>
  <result pre="(12 %) 6/42 (145 %) 6 Hayden et al. [25]" exact="Rimantadine" post="(≥1 year) 1987–1989 (A/H3N2, A/H1N1) Yes 11/61 (18 %)"/>
  <result pre="(18 %) 10/54 (19 %) 3 Hayden et al. [213]" exact="Zanamivir" post="(≥5 years) 1998–1999 (A/H3N2, B) Yes 7/414 (2 %)"/>
  <result pre="a persistent or an increasing number of virus-positive patients despite" exact="amantadine" post="prophylaxis. The recovery of the same genotype of resistant"/>
  <result pre="nursing home outbreak [58]. The frequency of instances in which" exact="amantadine" post="or rimantadine has failed to control outbreaks because of"/>
  <result pre="outbreak [58]. The frequency of instances in which amantadine or" exact="rimantadine" post="has failed to control outbreaks because of resistance emergence"/>
  <result pre="occasional patients wild-type virus replaces resistant variants after cessation of" exact="amantadine" post="[41]. As noted for some avian A/H7 viruses, this"/>
  <result pre="viral titers when resistance emerges as well [23]. Treatment Alternatives" exact="Amantadine" post="and rimantadine share susceptibility and resistance, so that resistance"/>
  <result pre="when resistance emerges as well [23]. Treatment Alternatives Amantadine and" exact="rimantadine" post="share susceptibility and resistance, so that resistance to one"/>
  <result pre="M2 inhibitor-resistant infections. Clinical studies suggest that both oseltamivir and" exact="zanamivir" post="are successful in terminating institutional outbreaks where amantadine resistance"/>
  <result pre="oseltamivir and zanamivir are successful in terminating institutional outbreaks where" exact="amantadine" post="resistance is proven or highly probable [58, 62, 63]."/>
  <result pre="62, 63]. In vitro testing suggests that the synthetic nucleosides" exact="ribavirin" post="and favipiravir are also inhibitory for M2 inhibitor-resistant influenza"/>
  <result pre="be an option. A small study randomized hospitalized adults to" exact="rimantadine" post="monotherapy or rimantadine-nebulized zanamivir combination therapy. The combination arm"/>
  <result pre="small study randomized hospitalized adults to rimantadine monotherapy or rimantadine-nebulized" exact="zanamivir" post="combination therapy. The combination arm had a trend to"/>
  <result pre="therapy [54]. Recently, a triple combination of amantadine, oseltamivir, and" exact="ribavirin" post="has been studied in vitro, in vivo, and in"/>
  <result pre="determine the genetic antiviral resistance profiles of the NA inhibitors" exact="zanamivir" post="and oseltamivir were initiated shortly after their development (reviewed"/>
  <result pre="late 1990s that served as the basis for approval of" exact="zanamivir" post="and oseltamivir in 1999 and, more recently, for approval"/>
  <result pre="in 1999 and, more recently, for approval of laninamivir and" exact="peramivir" post="[83–87]. Although zanamivir and oseltamivir have been available in"/>
  <result pre="more recently, for approval of laninamivir and peramivir [83–87]. Although" exact="zanamivir" post="and oseltamivir have been available in many countries since"/>
  <result pre="cell lines that stably overexpress human 2,6-sialyltransferase (SIAT1) to increase" exact="alpha" post="2,6-linked sialic acids may overcome this first limitation. However,"/>
  <result pre="patterns of cross-resistance are found for particular NA mutations. Importantly," exact="zanamivir" post="and laninamivir retain full inhibitory activity against variants with"/>
  <result pre="an His274Tyr are a reason for concern [122–124]. Resistance to" exact="zanamivir" post="was reported due to an amino change Gln136Lys [125,"/>
  <result pre="since 2013 causes high NA inhibitor resistance to oseltamivir and" exact="peramivir" post="and reduced resistance to zanamivir [138, 139]. Unlike A/H3N2"/>
  <result pre="inhibitor resistance to oseltamivir and peramivir and reduced resistance to" exact="zanamivir" post="[138, 139]. Unlike A/H3N2 viruses carrying the Arg292Lys amino"/>
  <result pre="zanamivir, and peramivir. Table 71.5 Representative studies of oseltamivir and" exact="zanamivir" post="susceptibility of field isolates of influenza A and B"/>
  <result pre="chain reaction aOne B/Perth/211/2001 isolate had ninefold reduced susceptibility to" exact="zanamivir" post="and 14-fold to oseltamivir compared to the mean inhibitory"/>
  <result pre="150]. Table 71.6 Frequency of resistance emergence to oseltamivir or" exact="zanamivir" post="during treatment Drug/study Population Assay Virus type No. isolates"/>
  <result pre="5 (15.6%) 4 His275Tyr Adults—hospitalized NAI, S 4 (13.3 %)" exact="Zanamivir" post="Barnett et al. [88] Adults NAI, S A +"/>
  <result pre="A/H3N2 and influenza B virus-infected patients treated with oseltamivir and" exact="zanamivir" post="with mutations in both the viral HA and NA"/>
  <result pre="inhibitor cross-resistance vary by virus type and subtype, such that" exact="zanamivir" post="retains inhibitory activity for the most common resistant variants"/>
  <result pre="that emerge during the therapeutic use of oseltamivir or peramivir." exact="Zanamivir" post="is fully inhibitory for oseltamivir-resistant variants possessing the Glu119Val"/>
  <result pre="in N1 [102, 172]. Depending on the virus and assay," exact="zanamivir" post="is partially inhibitory for resistant variants with Arg292Lys substitution"/>
  <result pre="type [102, 172–174]. There is controversy about the role of" exact="peramivir" post="in the management of variants that are resistant to"/>
  <result pre="mutation in influenza B NA that confers reduced susceptibility to" exact="zanamivir" post="[178]. Given these findings, most experts recommend using zanamivir"/>
  <result pre="to zanamivir [178]. Given these findings, most experts recommend using" exact="zanamivir" post="for the treatment of patients who develop resistance or"/>
  <result pre="patients who develop resistance or virologic failure to oseltamivir. Inhaled" exact="zanamivir" post="has been utilized in a few patients with variable"/>
  <result pre="is less likely in patients with influenza pneumonia [179–182]. Intravenous" exact="zanamivir" post="has been utilized most frequently for patients with proven"/>
  <result pre="prior exposure to numerous interventions [183–186]. Other NA inhibitors and" exact="zanamivir" post="dimers that have prolonged duration of antiviral effect after"/>
  <result pre="NA inhibitor prevention and perhaps treatment alternatives in the future." exact="Ribavirin" post="would also be expected to be inhibitory for influenza"/>
  <result pre="its use in human influenza infections due to such variants." exact="Ribavirin" post="combined with a NA inhibitor exerts additive to synergistic"/>
  <result pre="experimentally infected with influenza A, the combination of orally administered" exact="ribavirin" post="and peramivir was associated with improved survival relative to"/>
  <result pre="with influenza A, the combination of orally administered ribavirin and" exact="peramivir" post="was associated with improved survival relative to ribavirin alone"/>
  <result pre="ribavirin and peramivir was associated with improved survival relative to" exact="ribavirin" post="alone but not to peramivir alone [189]. A more"/>
  <result pre="with improved survival relative to ribavirin alone but not to" exact="peramivir" post="alone [189]. A more recent study found that a"/>
  <result pre="[189]. A more recent study found that a combination of" exact="ribavirin" post="and oseltamivir was no more effective than ribavirin alone"/>
  <result pre="combination of ribavirin and oseltamivir was no more effective than" exact="ribavirin" post="alone against a lethal influenza A(H1N1) infection but superior"/>
  <result pre="therapy. Given its slightly broader activity against most oseltamivir-resistant variants," exact="zanamivir" post="would be the preferred therapy for patients with proven"/>
  <result pre="nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virusJAMA2009301101042610.1001/jama.2009.29719255111 12.GubarevaLVet al.Evidence for" exact="zanamivir" post="resistance in an immunocompromised child infected with influenza B"/>
  <result pre="of influenza pandemic preparedness in developing countriesEmerg Infect Dis20081468758010.3201/eid1406.07083918507896 17.HaydenFGAokiFYBarriereSLAmantadine," exact="rimantadine" post="and related agentsAntimicrobial therapy and vaccines1999Baltimore, MDWilliams and Wilkins134465"/>
  <result pre="vaccines1999Baltimore, MDWilliams and Wilkins134465 18.BelsheRBet al.Genetic basis of resistance to" exact="rimantadine" post="emerging during treatment of influenza virus infectionJ Virol19886251508123282079 19.HayAJRichmanDDAmantadine"/>
  <result pre="treatment with rimantadinePediatrics1987802275823302925 24.BelsheRBet al.Resistance of influenza A virus to" exact="amantadine" post="and rimantadine: results of one decade of surveillanceJ Infect"/>
  <result pre="from 1994 to 2005: a cause for concernLancet2005366949211758110.1016/S0140-6736(05)67338-216198766 39.Hayden FG." exact="Amantadine" post="and rimantadine—clinical aspects. In: Richman DD, editor. Antiviral drug"/>
  <result pre="and H3N2J Clin Microbiol20034152164510.1128/JCM.41.5.2164-2165.200312734269 54.IsonMGet al.Safety and efficacy of nebulized" exact="zanamivir" post="in hospitalized patients with serious influenzaAntivir Ther2003831839012924534 55.KlimovAIet al.Prolonged"/>
  <result pre="M.G., M.A. Rocha Crispino Santos, and A.J. Alves da Cunha," exact="Amantadine" post="and rimantadine for influenza A in children and the"/>
  <result pre="Rocha Crispino Santos, and A.J. Alves da Cunha, Amantadine and" exact="rimantadine" post="for influenza A in children and the elderly. Cochrane"/>
  <result pre="amantadine-resistant influenza a viruses (H3N2) from patients following administration of" exact="amantadine" post="in JapanJ Clin Microbiol20013941652310.1128/JCM.39.4.000-000.200111283109 61.DegelauJet al.Amantadine-resistant influenza A in"/>
  <result pre="Ontario nursing homes, 1999–2000J Am Geriatr Soc20025046081610.1046/j.1532-5415.2002.50153.x11982659 63.HirjiZet al.Utility of" exact="zanamivir" post="for chemoprophylaxis of concomitant influenza A and B in"/>
  <result pre="One201052e933210.1371/journal.pone.000933220179772 66.NguyenJTet al.Efficacy of combined therapy with amantadine, oseltamivir, and" exact="ribavirin" post="in vivo against susceptible and amantadine-resistant influenza A virusesPLoS"/>
  <result pre="R Soc Interface201411922013108310.1098/rsif.2013.108324430126 83.SugayaNet al.Efficacy, safety, and pharmacokinetics of intravenous" exact="peramivir" post="in children with 2009 pandemic H1N1 influenza A virus"/>
  <result pre="Chemother20125613697710.1128/AAC.00132-1122024821 84.KohnoSet al.Phase III randomized, double-blind study comparing single-dose intravenous" exact="peramivir" post="with oral oseltamivir in patients with seasonal influenza virus"/>
  <result pre="efficacy studiesJ Antimicrob Chemother.2000441788710.1128/AAC.44.1.78-87.2000 89.KawaiNet al.Clinical effectiveness of oseltamivir and" exact="zanamivir" post="for treatment of influenza A virus subtype H1N1 with"/>
  <result pre="cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and" exact="peramivir" post="in Japan, November to December 2013Euro Surveill.20141912066610.2807/1560-7917.ES2014.19.1.2066624434172 125.HurtACet al.Zanamivir-resistant"/>
  <result pre="a Q136K mutation in the neuraminidase gene is resistant to" exact="zanamivir" post="but exhibits reduced fitness in the guinea pig transmission"/>
  <result pre="backgroundsAntivir Ther2006118971617302366 173.MishinVPet al.Evaluation of methyl inosine monophosphate (MIMP) and" exact="peramivir" post="activities in a murine model of lethal influenza A"/>
  <result pre="fitness and transmissibilityAntimicrob Agents Chemother2005491040758410.1128/AAC.49.10.4075-4084.200516189083 175.Abed Y et al. Parenteral" exact="peramivir" post="treatment for Oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses."/>
  <result pre="Infect Dis. 2011;204(10):1641–2; author’s reply 1642–3. 176.AbedYPizzornoABoivinGTherapeutic activity of intramuscular" exact="peramivir" post="in mice infected with a recombinant influenza A/WSN/33 (H1N1)"/>
  <result pre="(H1N1) 2009, United StatesEmerg Infect Dis2011172255710.3201/eid1702.10172421291599 181.JohnyAAet al.The use of" exact="zanamivir" post="to treat influenza A and B infection after allogeneic"/>
  <result pre="Marrow Transplant2002292113510.1038/sj.bmt.170334311850704 182.PetersenEet al.Failure of combination oral oseltamivir and inhaled" exact="zanamivir" post="antiviral treatment in ventilator- and ECMO-treated critically ill patients"/>
  <result pre="A (H1N1)vScand J Infect Dis2011436–749550310.3109/00365548.2011.55614421309638 183.Chan-TackKMet al.Clinical experience with intravenous" exact="zanamivir" post="under an emergency investigational new drug program in the"/>
  <result pre="the United StatesJ Infect Dis20132071196810.1093/infdis/jis63723089591 184.Chan-TackKMet al.Clinical experience with intravenous" exact="zanamivir" post="under an Emergency IND program in the United States"/>
  <result pre="States (2011–2014)Antivir Ther2015205561410.3851/IMP294425667992 185.FraaijPLet al.Evaluation of the antiviral response to" exact="zanamivir" post="administered intravenously for treatment of critically ill patients with"/>
  <result pre="cell culture and in mice with the cyclopentane neuraminidase inhibitor" exact="RWJ-270201" post="and ribavirinChemotherapy2002482889310.1159/00005766812011541 189.SmeeDFet al.Activities of oseltamivir and ribavirin used"/>
  <result pre="neuraminidase inhibitor RWJ-270201 and ribavirinChemotherapy2002482889310.1159/00005766812011541 189.SmeeDFet al.Activities of oseltamivir and" exact="ribavirin" post="used alone and in combination against infections in mice"/>
  <result pre="virusesAntivir Chem Chemother20061741859210.1177/09563202060170040317066897 190.SeoSet al.Combination therapy with amantadine, oseltamivir and" exact="ribavirin" post="for influenza A infection: safety and pharmacokineticsAntivir Ther20131833778610.3851/IMP247523264438 191.FurutaYet"/>
  <result pre="pneumonia: a future H5N1 treatment?Ann Intern Med2006145859960910.7326/0003-4819-145-8-200610170-0013916940336 202.ValetteMet al.Susceptibilities to" exact="rimantadine" post="of influenza A/H1N1 and A/H3N2 viruses isolated during the"/>
  <result pre="and 1989 to 1990Antimicrob Agents Chemother1993371022394010.1128/AAC.37.10.22398257151 203.ZieglerTet al.Low incidence of" exact="rimantadine" post="resistance in field isolates of influenza A virusesJ Infect"/>
  <result pre="influenza A virusesJ Infect Dis19991804935910.1086/31499410479115 204.DawsonJNeuraminidase inhibitor and amantadineLancet20003559222225410.1016/S0140-6736(05)72755-010881922 205.SuzukiHSaitoROshitaniHExcess" exact="amantadine" post="use and resistant virusesLancet20013589296191010.1016/S0140-6736(01)06919-711741673 206.ShihSRet al.Amantadine-resistant influenza A virus"/>
  <result pre="in Japan, 2005–2006N Engl J Med20073563312310.1056/NEJMc06298917229966 208.GalbraithAWet al.Protective effect of" exact="1-adamantanamine" post="hydrochloride on influenza A2 infections in the family environment:"/>
  <result pre="studyLancet1969276291026810.1016/S0140-6736(69)90639-44187541 209.BricaireFet al.Prevention of influenza A. Effectiveness and tolerance of" exact="rimantadine" post="hydrochloridePresse Med.199019269722137233 210.MontoASet al.Zanamivir prophylaxis: an effective strategy for"/>
  <result pre="in household contacts: a randomized controlled trialJAMA200128567485410.1001/jama.285.6.74811176912 212.GalbraithAWet al.Study of" exact="1-adamantanamine" post="hydrochloride used prophylactically during the Hong Kong influenza epidemic"/>
  <result pre="epidemic in the family environmentBull World Health Organ1969413677824908342 213.HaydenFGet al.Inhaled" exact="zanamivir" post="for the prevention of influenza in families. Zanamivir Family"/>
  <result pre="213.HaydenFGet al.Inhaled zanamivir for the prevention of influenza in families." exact="Zanamivir" post="Family Study GroupN Engl J Med2000343181282910.1056/NEJM20001102343180111058672 214.HaydenFGet al.Management of"/>
  <result pre="sequence analysis and susceptibilities of influenza virus clinical isolates to" exact="zanamivir" post="and oseltamivirAntimicrob Agents Chemother200347722647210.1128/AAC.47.7.2264-2272.200312821478 216.HurtACet al.Susceptibility of human influenza"/>
  <result pre="from Australasia and South East Asia to the neuraminidase inhibitors" exact="zanamivir" post="and oseltamivirAntiviral Res2004621374510.1016/j.antiviral.2003.11.00815026200 217.BoivinGGoyetteNSusceptibility of recent Canadian influenza A"/>
  <result pre="the 2000–2002 influenza seasonsVirus Res20041031-2195710.1016/j.virusres.2004.02.03315163509 219.FerrarisOKesslerNLinaBSensitivity of influenza viruses to" exact="zanamivir" post="and oseltamivir: a study performed on viruses circulating in"/>
 </snippets>
</snippetsTree>
